Select Language
CTLA-4
CTLA-4 Overview
| English Name | Cytotoxic T-Lymphocyte-Associated Antigen 4 | Approved Drugs | 5 |
| Drugs in Clinical Trials | 64 | Target Synonym | Celiac Disease 3，Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4，Cytotoxic T-Lymphocyte Protein 4，CD152，Cytotoxic T-lymphocyte-associated antigen 4，CTLA4，CTLA-4，Cytotoxic T-Lymphocyte Associated Protein 4，Insulin-Dependent Diabetes Mellitus 12，Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form，Cytotoxic T-Lymphocyte-Associated Serine Esterase-4，CD152 Isoform，CD152 Antigen，CELIAC3，IDDM12，ALPS5，GRD4，GSE，CD，CTLA-4 Antigen |
| Highest Development Stage | Approved | ||
| English Name | Cytotoxic T-Lymphocyte-Associated Antigen 4 |
| Target Synonym | Celiac Disease 3，Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4，Cytotoxic T-Lymphocyte Protein 4，CD152，Cytotoxic T-lymphocyte-associated antigen 4，CTLA4，CTLA-4，Cytotoxic T-Lymphocyte Associated Protein 4，Insulin-Dependent Diabetes Mellitus 12，Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form，Cytotoxic T-Lymphocyte-Associated Serine Esterase-4，CD152 Isoform，CD152 Antigen，CELIAC3，IDDM12，ALPS5，GRD4，GSE，CD，CTLA-4 Antigen |
| Approved Drugs | 5 |
| Drugs in Clinical Trials | 64 |
| Highest Development Stage | Approved |
CTLA-4 Product List
- Product Category
Protein (19)Kits (2)Antibody (1)
- Product Status
Launched (22)
- Species
Human (11)Cynomolgus / Rhesus macaque (4)Mouse (5)Rat (2)
- Tag
His Tag (6)Fc Tag (4)Strep Tag (1)His Tag & Avi Tag (4)Fc Tag & Avi Tag (3)Mouse IgG Fc Tag (1)- (3)
- Conjugate
Unconjugated (11)Biotin-labeled (7)- (2)PE Labeled (2)
Total: 22
- 1
- 2
- 3
CTLA-4 Background
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
CTLA-4 Synonyms
CTLA4,CD152
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CS-1002 | CS-1002; SHR-8068 | Phase 3 Clinical | Cstone Pharmaceuticals | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Botensilimab | AGEN-1181 | Phase 3 Clinical | Agenus Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Sturlimogene Erparepvec | RP-2 | Phase 3 Clinical | Replimune Group Inc | Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Precancerous Conditions; Stomach Neoplasms; Uveal melanoma | Details |
| Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Anorectal disorders; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Melanoma; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | Details |
| Volrustomig | MEDI5752; MEDI-5752 | Phase 3 Clinical | Medimmune Llc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Ipilimumab biosimilar (Henlius) | HLX13 | Phase 3 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Solid tumours | Details | |
| Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Melanoma; Skin Melanoma | Details |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D（China）Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| Futermestotug | YH-001 | Phase 2 Clinical | Alopecia Areata; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma; Solid tumours | Details | |
| Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| BMS-986288 | BMS-986288 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | BeOne Medicines Ltd, Bioatla | Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Ankang Biotechnology Co Ltd | Melanoma | Details | |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| Belatacept biosimilar (Alphamab) | KN-019 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Arthritis, Rheumatoid; Rejection of renal transplantation | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | Details | |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| Quavonlimab | AK-107; MK-1308 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details | |
| Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody AG, Ludwig Institute For Cancer Research | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Hemangiosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Neuroendocrine Tumors; Solid tumours | Details |
| JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms | Details |
| Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| Apalulizumab | Phase 2 Clinical | Shanghai Rui Jin Hospital | Pancreatic Neoplasms | Details | |
| Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours | Details |
| LM-168 | LM-168 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours | Details |
| HX-044 | HX044; HX-044 | Phase 2 Clinical | Hanx Biopharmaceuticals Pty Ltd | Lymphoma; Solid tumours | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Neoplasms; Solid tumours | Details |
| CS-2009 | CS-2009 | Phase 2 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | Details |
| HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 2 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Efzilonkofusp alfa | GI-102 | Phase 2 Clinical | GI Innovation Inc | Astrocytoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Gliosarcoma; Liver Neoplasms; Melanoma; Ovarian Neoplasms; Skin Melanoma; Soft Tissue Neoplasms; Solid tumours | Details |
| SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 2 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| IMM-27M | IMM-27M; IMM27M; SYN27M; SYN-27M | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms; Pathologic Processes; Solid tumours | Details | |
| Vilastobart | XTX-101; XTX101 | Phase 2 Clinical | Xilio Development Inc | Colorectal Neoplasms | Details |
| RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Solid tumours | Details |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| JS-007 | JS007; JS-007 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Carcinoma, Hepatocellular; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 1 Clinical | Bristol-Myers Squibb Company | Adrenal Gland Neoplasms; Liver Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
| SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
| GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours | Details |
| CTLA-4 Mab (Beijng Immunoah Pharma Tech) | 5E3 (Beijng Immunoah Pharma Tech); CTLA-4 Mab (Beijng Immunoah Pharma Tech) | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
| GB-268 | GB268 | Phase 1 Clinical | Genor Biopharma Co Ltd | Neoplasms; Solid tumours | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| GK-201 | GK201; GK-201 | Phase 1 Clinical | Suzhou Guokuang Pharmaceutical Tech Co Ltd | Solid tumours | Details |
| STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Anus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| IMD-303 | IMD-303; IMD303 | Phase 1 Clinical | Shanghai Affinity Biopharmaceutical Co Ltd | Solid tumours | Details |
| Imiquimod/Zalifrelimab | UGN-302; UGN-201+UGN-301 | Phase 1 Clinical | Urogen Pharma | Urinary Bladder Neoplasms | Details |
| TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Melanoma; Solid tumours | Details |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cadonilimab | AK-104; AK104 | Approved | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms | Details | |
| Ipilimumab | 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010 | Approved | Bristol-Myers Squibb Company | Yervoy, 逸沃 | United States | Melanoma | Bristol-Myers Squibb Company | 2011-03-25 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adrenocortical Carcinoma; Angioimmunoblastic T-cell Lymphoma; Anus Neoplasms; Brain metastases; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Embryonal; Carcinoma, Endometrioid; Carcinoma, Giant Cell; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endodermal Sinus Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Gestational Trophoblastic Disease; Glioblastoma; Gliosarcoma; Hemangiosarcoma; HIV I | Details |
| IpilimumabN01 (Innovent Biologics) | IBI-310 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯欣 | Mainland China | Colonic Neoplasms | Innovent Biologics Inc | 2025-12-22 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Microsatellite Instability; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Hepatocellular | Astrazeneca Ab | 2022-10-21 | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Cystadenoma, Serous; Digestive System Diseases; Dysgerminoma; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatitis C, Chronic; HIV Infections; Hydronephrosis; Kidney Neoplasms; Klatskin Tumor; Laryngeal Diseases; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Melanoma; Mesothelioma; Metastatic breast cancer; Microsatel | Details |
| Iparomlimab/Tuvonralimab | PBS-103/PBS-105; QL-1706; PSB-205 | Approved | Qilu Pharmaceutical Co Ltd | 齐倍安 | Mainland China | Uterine Cervical Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-09-26 | Adenocarcinoma of Lung; Biliary Tract Neoplasms; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Diseases; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Intraepithelial Lesions of the Cervix; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
Product Reviews
J***o2023-02-03
1People LikeBought as potential coating protein to be used in ELISA to detected expressed Anti-CTLA-4. Vials arrived promptly and very well packaged. The website is informative and very intuitive to navigate to be able to find the product best suited for your needs. MSDS, CofA and Dataheets are readily available and contain accurate and comprehensive information e.g. storage temperatures, glycosylation information and purity- the guidance for usage of the protein was especially useful to serve as a jumping off point for coating concentrations. Results so far have been very promising which is what I have come to expect from ACROBiosystems- great work!- J***r2022-01-11 0People LikeThe product came in packaged properly and with proper documentation. CoAs were clear as to when the product would expire, both in the lyophilized state and reconstituted. Instructions for reconstitution were also clear. The packaging made it easy to quickly transfer the product to the appropriate storage. Package was shipped in a reasonable timeline. Details for the product were easy to find, which was extremely helpful for entering into our system.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to: